Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with or without atezolizumab in advanced malignancies
2018-000390-67Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab and atezolizumab in hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), epithelial ovarian cancer (EOC) and 1 more (2 arms), sponsored by Sanofi. Primary endpoint: Dose-limiting toxicities. Started Apr 2018; status: completed.
02
Drugs
isatuximabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)epithelial ovarian cancer (EOC)glioblastoma (GBM)
Beyond the preview
Go deeper on 2018-000390-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000390-67.